Analyzing the impact of metabolites on drug candidates
Syngene offers comprehensive metabolite identification and biotransformation services in world-class facilities to help clients assess the safety and fate of lead compounds. Our assays help optimize compound clearance in the early drug discovery stage by identifying and modifying metabolically labile soft spots.
Our experienced team works on profiling, identifying, and analyzing metabolites using in vitro studies in microsomes, hepatocytes, recombinant metabolizing enzymes, and plasma among others. We are also proficient in conducting preclinical in vivo studies in plasma or blood from rodent species, among others.
Capabilities
Our team measures critical information such as the exact mass and structural elucidation data of metabolites using liquid chromatography (LC) coupled with high-resolution mass spectrometry (HRMS) and mass spectrometry (MS) based analytical methods. Our LC-HRMS/MS systems include the AB Sciex Triple TOF 5600+, AB Sciex 5500 QTrap and AB Sciex 6500+ series, and photodiode array (PDA) detectors help accurately quantify metabolites.
The assays we offer include:
- Intrinsic clearance (CLint) and high-level profiling of the top three metabolites in liver microsomes and hepatocytes
- Metabolite soft spot analysis
- Metabolite fingerprinting
- High-throughput reactive metabolite screening
